Intravitreal 0.19 mg fluocinolone acetonide implant in non-infectious uveitis

• Verfasst von: Hikal, Muaas [VerfasserIn]
• Verfasst von: Celik, Nil [VerfasserIn]
• Verfasst von: Auffarth, Gerd U. [VerfasserIn]
• Verfasst von: Kessler, Lucy Joanne [VerfasserIn]
• Verfasst von: Mayer, Christian [VerfasserIn]
• Verfasst von: Khoramnia, Ramin [VerfasserIn]
• Titel: Intravitreal 0.19 mg fluocinolone acetonide implant in non-infectious uveitis
• Verf.angabe: Muaas Hikal, Nil Celik, Gerd Uwe Auffarth, Lucy Joanne Kessler, Christian Steffen Mayer and Ramin Khoramnia
• E-Jahr: 2021
• Jahr: 1 September 2021
• Umfang: 14 S.
• Fussnoten: Gesehen am 18.10.2021
• Titel Quelle: Enthalten in: Journal of Clinical Medicine
• Ort Quelle: Basel : MDPI, 2012
• Jahr Quelle: 2021
• Band/Heft Quelle: 10(2021), 17, Artikel-ID 3966, Seite 1-14
• ISSN Quelle: 2077-0383
• DOI: doi:10.3390/jcm10173966
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: 0.19-mg fluocinolone acetonide implant
• Sach-SW: non-infectious uveitis
• Sach-SW: uveitic macular edema
• K10plus-PPN: 1774336316

Abstract

The efficacy of the 0.19-mg fluocinolone acetonide (FAc) intravitreal implant (ILUVIEN) in the treatment of non-infectious uveitic macular edema (UME) was assessed on twenty-six patients (34 eyes) with non-infectious UME between 2013 and 2020, in a mean follow-up of 18 ± 19.3 (mean ± SD) months. Macular edema was resolved in 24 (70.6%) cases. Five of these eyes had a relapse after 23.2 ± 14 months. Three FAc reinjections were performed and a drying of the macula was observed. After FAc implantation, 24 eyes (70.6%) were completely dry; central retinal thickness (CRT) decreased in 6 eyes (17.6%), but residual intraretinal fluid was still evident. In 20 eyes (58.5%), visual acuity (VA) improved (from +1 to +5 lines) and remained stable in 9 eyes (26.5%). Thirty eyes (88.2%) were pseudophakic at baseline and four were phakic. Three of these eyes had a cataract prior to therapy and the other developed a cataract 2.5 years after the FAc implant was administered. There was an overall increase in intraocular pressure (IOP; +4.4 ± 3.7 mmHg) and eye drops were required in three eyes. The FAc implant led to long-term improvements in mean CRT and VA, and that the side-effect profile was manageable in a clinical setting in patients with non-infectious UME.